The prevalent cases of NMO vary worldwide, In the USA the estimated prevalence is to be approximately 2% to 2.5% that of MS, NMO accounts for a small proportion of demyelinating disease in Caucasians (1–2%), but a much larger percentage in Asians (20–48%). Women are preferentially affected with a female: male ratio of nearly 10:1

Read more:- Neuromyelitis optica (NMO) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 

Neuromyelitis-optica-NMO-forecast

 

Comprehensive insight on patient segmentation based on age, sex, Diagnosis (NMO-IgG Seropositive, NMO-IgG Seropositive), Clinical Characterization based on Acute & Refractory; Transverse Myelitis (Overall, Longitudinally extensive, Focal), Optic Neuritis (Overall, Unilateral, Bilateral), Event types (Transverse Myelitis, Optic Neuritis; Monophasic & Recurrent, has been provided into the epidemiology section of the Neuromyelitis Optica (NMO) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

 

CI IMAGE

 

In terms of pharmacologic therapies, there are several drug candidates are in different Phase (II and I/II/ III) stages of development. Key companies are Horizon Pharma, Alexion Pharma, Roche, Viro-Pharma, TG Therapeutics, Bio-Thera, Novartis. Among these key assets, some of the assets is being designated as an orphan drug from EMA and US FDA. The launch of key assets will positively impact the overall market from 2023 to 2030 in 8 MM countries. In March 2016, The U.S. Food and Drug Administration (FDA) granted the drug orphan drug designation for the treatment of NMO and NMOSD. In March 2017, the EMA granted Orphan designation to inebilizumab (formerly MEDI-551) for the treatment of Neuromyelitis Optica spectrum disorder (NMOSD).

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Otoferlin Gene-Mediated Hearing Loss – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Treatment-resistant depression (TRD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Systemic lupus erythematosus (SLE) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Propionic acidemia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Achromatopsia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

[email protected]

[email protected]

Tags: Neuromyelitis optica (NMO), Neuromyelitis optica (NMO) market outlook report, Neuromyelitis optica (NMO) competitive landscape, Neuromyelitis optica (NMO) market forecast